| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | HAE | Common Stock | Tax liability | $7,275 | -76 | -0.54% | $95.73 | 14,084 | 17 May 2024 | Direct | F1, F2 |
| transaction | HAE | Common Stock | Award | +2,089 | +15% | 16,173 | 17 May 2024 | Direct | F2, F3, F4 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | HAE | Non-qualified Stock Option (Right to Buy) | Award | $0 | +4,591 | $0.000000 | 4,591 | 17 May 2024 | Common Stock | 4,591 | $95.73 | Direct | F5 |
| Id | Content |
|---|---|
| F1 | Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. |
| F2 | This number includes unvested RSUs previously reported. |
| F3 | The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. |
| F4 | Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. |
| F5 | Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. |